Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil

Autor: Fernandes, Brígida Dias, D’Athayde Rodrigues, Fernanda, Cardoso Cirilo, Hérica Núbia, Borges, Stéfani Sousa, Krug, Bárbara Corrêa, Probst, Livia Fernandes, Zimmermann, Ivan
Zdroj: In Value in Health Regional Issues March 2024 40:108-117
Databáze: ScienceDirect
Externí odkaz: